These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30739498)

  • 1. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
    Nguyen B; Foisy MM; Hughes CA
    Ann Pharmacother; 2019 Aug; 53(8):833-844. PubMed ID: 30739498
    [No Abstract]   [Full Text] [Related]  

  • 2. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
    d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
    J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
    Chouchana L; Beeker N; Treluyer JM
    J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
    Baldin G; Ciccullo A; Capetti A; Rusconi S; Sterrantino G; Cossu MV; Giacomelli A; Lagi F; Latini A; Bagella P; De Luca A; Di Giambenedetto S; Madeddu G
    HIV Med; 2019 Feb; 20(2):164-168. PubMed ID: 30457197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse drug reactions to integrase strand transfer inhibitors.
    Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
    AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
    Llibre JM; Montoliu A; Miró JM; Domingo P; Riera M; Tiraboschi J; Curran A; Homar F; Ambrosioni J; Abdulghani N; Force L; Peraire J; Casabona J;
    HIV Med; 2019 Mar; 20(3):237-247. PubMed ID: 30688007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort.
    Cuzin L; Pugliese P; Katlama C; Bani-Sadr F; Ferry T; Rey D; Lourenco J; Bregigeon S; Allavena C; Reynes J; Cabié A;
    J Antimicrob Chemother; 2019 Mar; 74(3):754-760. PubMed ID: 30534993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
    Shah BM; Schafer JJ; Desimone JA
    Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
    Patel K; Huo Y; Jao J; Powis KM; Williams PL; Kacanek D; Yee LM; Chadwick EG; Shiau S; Jacobson DL; Brummel SS; Sultan-Beyer L; Kahlert CR; Zash R; Seage GR; ;
    N Engl J Med; 2022 Sep; 387(9):799-809. PubMed ID: 36053505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of HIV integrase inhibitors.
    Adams JL; Greener BN; Kashuba AD
    Curr Opin HIV AIDS; 2012 Sep; 7(5):390-400. PubMed ID: 22789987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolutegravir for the treatment of adult patients with HIV-1 infection.
    Wu G; Abraham T; Saad N
    Expert Rev Anti Infect Ther; 2014 May; 12(5):535-44. PubMed ID: 24694091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.
    van der Galiën R; Ter Heine R; Greupink R; Schalkwijk SJ; van Herwaarden AE; Colbers A; Burger DM
    Clin Pharmacokinet; 2019 Mar; 58(3):309-323. PubMed ID: 29915921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability of integrase inhibitors in a real-life setting.
    Peñafiel J; de Lazzari E; Padilla M; Rojas J; Gonzalez-Cordon A; Blanco JL; Blanch J; Marcos MA; Lonca M; Martinez-Rebollar M; Laguno M; Tricas A; Rodriguez A; Mallolas J; Gatell JM; Martinez E
    J Antimicrob Chemother; 2017 Jun; 72(6):1752-1759. PubMed ID: 28333231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.
    Massud I; Martin A; Dinh C; Mitchell J; Jenkins L; Heneine W; Pau CP; García-Lerma JG
    J Antimicrob Chemother; 2015 May; 70(5):1473-81. PubMed ID: 25630643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical use.
    Elliot E; Chirwa M; Boffito M
    Curr Opin Infect Dis; 2017 Feb; 30(1):58-73. PubMed ID: 27798496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrase inhibitor drugs during pregnancy and congenital anomalies: A case/non-case study from the global pharmacovigilance database VigiBase®.
    Saint-Lary L; Lacroix I; Leroy V; Sommet A
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1247. PubMed ID: 39086081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.
    Rimawi BH; Johnson E; Rajakumar A; Tao S; Jiang Y; Gillespie S; Schinazi RF; Mirochnick M; Badell ML; Chakraborty R
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy.
    Sibiude J; Le Chenadec J; Mandelbrot L; Dollfus C; Matheron S; Lelong N; Avettand-Fenoel V; Brossard M; Frange P; Reliquet V; Warszawski J; Tubiana R;
    AIDS; 2021 Feb; 35(2):219-226. PubMed ID: 33048878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
    Malet I; Gimferrer Arriaga L; Artese A; Costa G; Parrotta L; Alcaro S; Delelis O; Tmeizeh A; Katlama C; Valantin MA; Ceccherini-Silberstein F; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2014 Aug; 69(8):2118-22. PubMed ID: 24710029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.
    Mulligan N; Best BM; Wang J; Capparelli EV; Stek A; Barr E; Buschur SL; Acosta EP; Smith E; Chakhtoura N; Burchett S; Mirochnick M;
    AIDS; 2018 Mar; 32(6):729-737. PubMed ID: 29369162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.